Digital health company Hims & Hers has announced its expansion into at-home lab testing through the acquisition of Sigmund NJ LLC, marketed as Trybe Labs. The move will enable the company to offer comprehensive whole body testing and at-home blood draws, providing customers with deeper health insights and empowering providers with more data for personalized treatment plans.
The acquisition is expected to accelerate Hims & Hers’ growth in several new clinical categories, including low testosterone, perimenopausal, and menopausal support. The company plans to integrate these testing capabilities across its platform, enhancing its personalized offerings in nutrition, lifestyle, supplements, and medication.
Using a blood lancet that eliminates the need for needles or dried blood spot cards, customers will be able to access information about their hormone levels, cardiac risk, stress markers, cholesterol, liver function, thyroid function, and prostate health. This data will then help providers on the platform determine personalized treatment plans.
“The healthcare that customers expect and deserve today is on-demand care with treatments designed specifically for them. This next generation of healthcare is what we’re building at Hims & Hers by providing the best information and set of options to each customer that comes to our platform so they can access precisely the care that is best for them,” said Dr. Patrick Carroll, Chief Medical Officer of Hims & Hers. “Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient. At-home lab testing is one more exciting step towards elevating the personal, comprehensive care customers in this country should expect.”
Beyond immediate clinical applications, the company also plans to use de-identified lab data to enhance its AI developments, including its MedMatch by Hims & Hers system. This integration aims to advance the company toward delivering AI-powered healthcare experiences tailored to individual needs.
The New Jersey-based Trybe Labs acquisition was funded through cash on hand. Though the acquisition is complete, Hims & Hers expects to gradually roll out at-home testing to customers over the next year.
For many customers who come to the Hims & Hers platform seeking treatment for chronic conditions, these new testing capabilities could provide more comprehensive care options. The company emphasizes that the integration of at-home lab testing will allow them to deliver more precise data-backed treatment recommendations while maintaining their focus on accessibility and affordability.
